---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-073130"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:32:45.590726+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Relmada reports Q2 net loss $9.9M; NDV-01 91% overall response rate in NMIBC

## Summary
- Q2 net loss $9.9M ($0.30/shr) vs $17.8M ($0.59) a year ago; R&D expense fell to $2.8M from $10.7M.
- NDV-01 Phase 2: 91% complete response at any time; 90% at 6 months; no Grade 3+ TRAEs or discontinuations.
- Cash $20.6M at June 30, 2025, down from $44.9M at Dec 31, 2024; shares outstanding 33.2M.
- Phase 3 registration trial for NDV-01 planned for 1H 2026; Phase 2 for sepranolone in PWS in 1H 2026.
- No patients progressed to muscle-invasive disease or underwent cystectomy in the study.

## SEC filing metadata
- accession: 0001213900-25-073130
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390025073130/0001213900-25-073130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390025073130/ea0252310-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-073130
- JSON: https://secwatch.observer/filing/0001213900-25-073130.json
- Plain text: https://secwatch.observer/filing/0001213900-25-073130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.